The FDA approved adalimumab-bwwd (Hadlima, Samsung Bioepis), a biosimilar referencing adalimumab (Humira, AbbVie), for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn’s disease, ulcerative colitis and plaque psoriasis.